A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 10, 2010, Pages 678-687

  Oh, C ^a   Rengelshausen, J ^b   Mangold, B ^a   Etropolski, M ^a   Rauschkolb, C ^a   Wang, S S ^a   Upmalis, D ^a   Haufel T ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b GRÜNENTHAL GMBH   (Germany)

Author keywords

Electrocardiogram; Opioid; QT interval; Safety; Tapentadol

Indexed keywords

MOXIFLOXACIN; PLACEBO; TAPENTADOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SENSITIVITY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEART RATE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; HYPERHIDROSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NAUSEA; NEUROLOGIC DISEASE; NORMAL HUMAN; PRURITUS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; SOMNOLENCE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; VASCULAR DISEASE; VERTIGO; VOMITING;

EID: 77957658753     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48678     Document Type: Article

References (16)

1. Ahnve S. Correction of the QT interval for heart rate: review of different formulas and the use of Bazett's formula in myocardial infarction. Am Heart J. 1985; 109: 568-574. (Pubitemid 16256710)
2. Bazett HC. An analysis of time relations of electrocardiograms. Heart. 1920; 7: 353-367.
3. Daniels S, Casson E, Stegmann JU, Oh C, Okamoto A, Rauschkolb C, Upmalis D. Arandomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin. 2009; 25: 1551-1561.
4. Daniels SE, Upmalis D, Okamoto A, Lange C, Haeussler J. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin. 2009; 25: 765-776.
5. Fanoe S, Jensen GB, Sjøgren P, Korsgaard MP, Grunnet M. Oxycodone is associated with dose-dependent QTc prolongation in patients and lowaffinity inhibiting of hERG activity in vitro. Br J Clin Pharmacol. 2009; 67: 172-179.
6. Fridericia LS. The duration of systole in the electrocardiogram of normal subjects and patients with heart disease. Acta Medica Scand. 1920; 53: 469-486.
7. Hale M, Upmalis D, Okamoto A, Lange C, Rauschkolb C. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin. 2009; 25: 1095-1104.
8. Hartrick C, Van Hove I, Stegmann J-U, Oh C, Upmalis D. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther. 2009; 31: 260-271.
9. Pollard CE, Valentin J-P, Hammond TG. Strategies to reduce the risk of drug-induced QTinterval prolongation: a pharmaceutical company perspective. Br J Pharmacol. 2008; 154: 1538-1543.
10. Schneider J, Jahnel U, Linz K. Neutral effects of the novel analgesic tapentadol on cardiac repolarization due to mixed ion channel inhibitory activities. Drug Dev Res. 2010; doi:10.1002/ddr.20360.
11. Stegmann J-U, Weber H, Steup A, Okamoto A, Upmalis D, Daniels S. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. Curr Med Res Opin. 2008; 24: 3185-3196.
12. Straus SM, Sturkenboom MC, Bleumink GS, Dieleman JP, van der Lei J, de Graeff PA, Kingma JH, Stricker BH. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005; 26: 2007-2012. (Pubitemid 41435722)
13. 14C-labeled tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet. 2007; 32: 163-169.
14. Tzschentke TM, Christoph T, Kögel B, Schiene K, Hennies H-H, Englberger W, Haurand M, Jahnel U, Cremers TI, Friderichs E, De Vry J. (-)-(1R,2R)- 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)- phenol hydrochloride (tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007; 323: 265-276. (Pubitemid 47443277)
15. Tzschentke TM, De Vry J, Terlinden R, Hennies HH, Lange C, Strassburger W, Haurand M, Kolb J, Schneider J, Buschmann H, Finkam M, Jahnel U, Friderichs E. Tapentadol HCl. Drugs Future. 2006; 31: 1053-1061.
16. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Rockville, MD: Center for Drug Evaluation and Research (CDER); 2005.